clinical dataNovartis breaks BTK losing streak in multiple sclerosisNovartis’ remibrutinib has beaten teriflunomide in two Phase 3 trials in relapsing multiple sclerosis (MS), adding another important clinical win for a class of BTK inhibitors that has endured several … more ➔
licensingRoche reloads B-cell strategy with $1.53B Simcere dealRoche has licensed Simcere Zaiming’s preclinical trispecific antibody SIM0660, paying $75 million (€65 million) upfront in a deal potentially worth $1.53 billion (€1.32 billion). more ➔
Neurodegenerative DisordersAmyl Tx raises €8.25M to develop universal neurodegeneration drugBelgian biotech Amyl Therapeutics has completed an €8.25 million Series A extension to fund work on its universal treatment for neurodegenerative diseases. more ➔
artificial intelligenceAdaptyv raises $40M for AI-run wet labsSwiss biotech Adaptyv has raised a $40 million (€34.5 million) Series A to expand its automated protein-testing labs, betting that wet-lab capacity will become a critical bottleneck as AI models generate … more ➔
NovartisCAR-TNovartis: Three deaths put CAR-T expansion into autoimmune diseases on holdNovartis has paused eight clinical trials of its CD19 CAR-T therapy rap-cel after three patients died from a severe immune reaction. The studies are evaluating the therapy in autoimmune and neurological … more ➔
cardiologyESC 2026: Five stories that mattered in MunichLast weekend, from August 28 to 31, the European Society of Cardiology (ESC) held its annual congress in Munich. For the biotech industry, ESC 2026 delivered a mixed bag: a cardiac myosin inhibitor opening … more ➔
RNA TechnologiesMolecular surgery: How Europe can lead the worldKJ Muldoon’s survival was not just a medical breakthrough. It was a glimpse of a new category of medicine, in which a genetic error can be corrected with the precision of an operation rather than developed … more ➔
clinical dataBioNTech cancer vaccine trial halted after survival imbalanceBioNTech and Genentech have terminated a Phase 2 trial of their personalized mRNA cancer vaccine autogene cevumeran in colorectal cancer after more deaths occurred in the vaccine arm than among patients … more ➔
licensingHeidelberg Pharma deepens ADC alliance with HuadongGerman biotech Heidelberg Pharma and China-based Huadong Medicine are drawing ever closer: What began as a licensing partnership has developed into an alliance spanning capital investment, joint ADC … more ➔
startupsRevealis enters cancer vaccine race with TEIPP strategyDutch startup Revealis Biotherapeutics has launched to develop a new generation of cancer vaccines targeting tumor cells that have become difficult for T cells to recognize, building on an academic program … more ➔
Novartis
